|
Treatment Options
|
MAO-B Inhibitors
Selegiline (Eldepryl) may be considered for use in individuals with intact cognitive function (that is, the ability to think, reason, remember, imagine, or learn) who aren't functionally disabled.
Selegiline is also FDA approved for use in later stages of Parkinson's disease to boost the effects of levodopa and carbidopa. Insomnia and jitteriness are two common side effects of selegiline. Due to the increased effects of carbidopa and levodopa, worsening of involuntary movements, delusions, and hallucinations may also occur.
Drugs in the class
Selegiline Capsules (Eldepryl Capsules) |
Note: The above information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist, or other healthcare professional. It is not intended to diagnose a health condition, but it can be used as a guide to help you decide if you should seek professional treatment or to help you learn more about your condition once it has been diagnosed.
|
